Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus  

作　　者：Dong-Hua Liu Xiao-Ming Dong Wen-Jie Long 

机构地区：[1]The First Clinical Medical College,Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong Province,China [2]Department of Geriatrics,The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong Province,China

出　　处：《World Journal of Clinical Cases》2024年第36期6935-6938,共4页世界临床病例杂志（英文）

基　　金：Supported by the Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine,No.2022ZYYJ01;Guangzhou Municipal Science and Technology Bureau's 2024 Basic and Applied Basic Research Topic,No.2024A04J4254.

摘　　要：Coronary heart disease and type 2 diabetes mellitus(T2DM)often co-occur,presenting substantial health risks,particularly following acute myocardial infarction(AMI).While percutaneous coronary intervention(PCI)is a prevalent treatment,complications such as microvascular dysfunction may lead to heart failure,necessitating additional therapies.This editorial examines the emerging roles of sacubitril/valsartan and sodium-glucose co-transporter 2 inhibitors in managing post-PCI.Recent research investigates the combined effects of dapag-liflozin and telmisartan on myocardial microperfusion in post-AMI heart failure patients with T2DM.The findings suggest that this combination enhances myo-cardial microcirculation,improves cardiac function,and achieves better glycemic control,with a reduced incidence of major adverse cardiovascular events.Despite ongoing challenges,the integration of dapagliflozin and sacubitril/valsartan re-presents a significant advancement in post-AMI care.Further investigation in larger cohorts and more diverse patient populations is required to confirm its long-term clinical outcomes.

关 键 词：Heart failure Type 2 diabetes mellitus DAPAGLIFLOZIN Sacubitril Cardiovascular outcomes 

分 类 号：R587.1[医药卫生—内分泌] R542.22[医药卫生—内科学]